Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Aliza Rozenberg"'
Autor:
Meir Schechter, Cheli Melzer Cohen, Alisa Fishkin, Aliza Rozenberg, Ilan Yanuv, Dvora R. Sehtman-Shachar, Gabriel Chodick, Alice Clark, Trine J. Abrahamsen, Jack Lawson, Avraham Karasik, Ofri Mosenzon
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-12 (2023)
Abstract Background In clinical trials enrolling patients with type 2 diabetes (T2D) at high cardiovascular risk, many glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improved albuminuria status and possibly mitigated kidney function loss. Howe
Externí odkaz:
https://doaj.org/article/9521c0be51314f39acf728abf59b4868
Autor:
Dor Genzel, Lior H. Katz, Rifaat Safadi, Aliza Rozenberg, Yael Milgrom, Jeremy M. Jacobs, Asher Shafrir
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
IntroductionFrailty is a known risk factor for many diseases, including COVID-19. However, many frail patients are undiagnosed as the diagnosis can be cumbersome. Alanine transaminase (ALT) is found not only in the liver but also in the muscle tissue
Externí odkaz:
https://doaj.org/article/f78ab6d167da4a7ba3e8864191409ea7
Autor:
Meir Schechter, Cheli Melzer Cohen, Ilan Yanuv, Aliza Rozenberg, Gabriel Chodick, Johan Bodegård, Lawrence A. Leiter, Subodh Verma, Hiddo J. Lambers Heerspink, Avraham Karasik, Ofri Mosenzon
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-9 (2022)
Abstract Background Type-2 diabetes (T2D), chronic kidney disease, and heart failure (HF) share epidemiological and pathophysiological features. Although their prevalence was described, there is limited contemporary, high-resolution, epidemiological
Externí odkaz:
https://doaj.org/article/f4e41b35e48048809e9286d06c138961
Autor:
Meir Schechter, Cheli Melzer-Cohen, Aliza Rozenberg, Ilan Yanuv, Gabriel Chodick, Avraham Karasik, Mikhail Kosiborod, Ofri Mosenzon
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-12 (2021)
Abstract Background Randomized controlled trials showed that sodium/glucose cotransporter-2 inhibitors (SGLT2i) protect the heart and kidney in an array of populations with type 2 diabetes (T2D) and increased cardiorenal risk. However, the extent of
Externí odkaz:
https://doaj.org/article/183d926e22824f2198fce8d59b95f101
Autor:
Ofri Mosenzon, Itamar Raz, Stephen D. Wiviott, Meir Schechter, Erica L. Goodrich, Ilan Yanuv, Aliza Rozenberg, Sabina A. Murphy, Thomas A. Zelniker, Anna Maria Langkilde, Ingrid A.M. Gause-Nilsson, Martin Fredriksson, Peter A. Johansson, John P.H. Wilding, Darren K. McGuire, Deepak L. Bhatt, Lawrence A. Leiter, Avivit Cahn, Jamie P. Dwyer, Hiddo J.L. Heerspink, Marc S. Sabatine
Publikováno v:
Diabetes Care, 45(10), 2350-2359. AMER DIABETES ASSOC
OBJECTIVE In patients with moderate to severe albuminuric kidney disease, sodium–glucose cotransporter 2 inhibitors reduce the risk of kidney disease progression. These post hoc analyses assess the effects of dapagliflozin on kidney function declin
Autor:
Roni Weinberg Sibony, Julio Wainstein, Maya Ish Shalom, Tali Ganz, Aliza Rozenberg, Ilan Yanuv, Uri Eliyahu, Itamar Raz
Publikováno v:
Diabetes/Metabolism Research and Reviews. 39
Autor:
Faina Tsodikov, Meir Schechter, Rebecca Goldsmith, Lilach Peleg, Vered Baloush-Kleinman, Aliza Rozenberg, Ilan Yanuv, Yuri Gimelfarb, Ofri Mosenzon, Ronit Endevelt
Publikováno v:
International Journal of Obesity. 46:926-934
Cardiometabolic disorders contribute to morbidity and mortality in people with severe mental illnesses (SMI), yet lifestyle-intervention efficacy in patients with SMI is unclear. Israel's unique mental-health rehabilitation hostels (MHRHs) provide ho
Autor:
Orit Kliuk Ben Bassat, Meir Schechter, Natalia Ashtamker, Ilan Yanuv, Aliza Rozenberg, Boaz Hirshberg, Ayelet Grupper, Nachum Vaisman, Silviu Brill, Ofri Mosenzon
Publikováno v:
Clinical Kidney Journal.
Background Chronic pain is prevalent but difficult to treat in patients undergoing hemodialysis (HD). Effective and safe analgesics are limited in this patient population. Our aim of this feasibility study was to evaluate the safety of sublingual oil
Autor:
MEIR SCHECHTER, CHELI MELZER COHEN, ALIZA ROZENBERG, ILAN YANUV, GABRIEL CHODICK, OFRI MOSENZON, AVRAHAM KARASIK
Publikováno v:
Diabetes. 71
Kidney-protective effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) are supported by both randomized control trials and real world evidence in high cardiorenal risk type 2 diabetes mellitus (T2DM) patients. However, long-term efficacy stu
Autor:
Avivit Cahn, Stephen D. Wiviott, Ofri Mosenzon, Erica L. Goodrich, Sabina A. Murphy, Ilan Yanuv, Aliza Rozenberg, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Anna Maria Langkilde, Marc S. Sabatine, Itamar Raz
Publikováno v:
Diabetes care. 45(4)
OBJECTIVE Current guidelines recommend prescribing SGLT2 inhibitors to patients with type 2 diabetes and established or at high risk for atherosclerotic cardiovascular disease (ASCVD), irrespective of HbA1c levels. We studied the association of HbA1c